US Bancorp
ITRM

US Bancorp’s Iterum Therapeutics ITRM Stock Holding History

US Bancorp’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-133
Closed -$1K – 4140
2022
Q1 		$1K Hold
133
– – ﹤0.01% 3952
2021
Q4 		$1K Hold
133
– – ﹤0.01% 3990
2021
Q3 		$1K Hold
133
– – ﹤0.01% 3984
2021
Q2 		$5K Sell
133
-134
-50% -$2.91K ﹤0.01% 3612
2021
Q1 		$6K Buy
+267
New +$6.36K ﹤0.01% 3451

Other funds holding ITRM

CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KF
Krilogy Financial St. Louis, Missouri $3.11B AUM 20.67% 1-Year Est. Return
GC
Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return

US Bancorp's ITRM Position: Q2 2022 in Review

US Bancorp sold out of Iterum Therapeutics (ITRM) in Q2 2022, closing a stake of 133 shares — an estimated $1K sold.

US Bancorp first reported a position in ITRM in Q1 2021 and held it in 5 quarters. The position peaked at $6K in Q1 2021. 38 funds tracked by Wall St. Rank hold ITRM as of Q2 2022.

  • US Bancorp reported no remaining Iterum Therapeutics position as of Q2 2022 after selling out during the quarter.
  • US Bancorp sold 133 Iterum Therapeutics shares in Q2 2022, an estimated $1K.
  • US Bancorp first reported a position in Iterum Therapeutics in Q1 2021 and held it in 5 quarters.
  • US Bancorp's Iterum Therapeutics position peaked at $6K in Q1 2021.
  • 38 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q2 2022.

Based on US Bancorp's 13F filing for Q2 2022, filed 1 Aug 2022.